{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:13:32Z","timestamp":1793578412139,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cpcardiol.2026.103352","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:58:53Z","timestamp":1776873533000},"page":"103352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quadruple therapy in heart failure: Why, when, and in whom?"],"prefix":"10.1016","volume":"51","author":[{"given":"Ioannis","family":"Paraskevaidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Tsougos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4348-2153","authenticated-orcid":false,"given":"Christos","family":"Kourek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2026.103352_bib0001","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0002","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0003","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0004","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0005","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0006","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0007","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.jacc.2025.08.054","article-title":"Pharmacologic treatment of heart failure with reduced ejection fraction: an updated systematic review and network meta-analysis","volume":"86","author":"van Essen","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomized controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0010","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0011","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0012","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure: optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0013","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40256-024-00646-4","article-title":"Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits","volume":"24","author":"Zhang","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0014","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0016","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the SAVE trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0018","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0019","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0020","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0021","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0023","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0025","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.2644","article-title":"Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"24","author":"Lindberg","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0026","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00392-024-02498-z","article-title":"Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection fraction spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020","volume":"113","author":"Karlstr\u00f6m","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","article-title":"Novel RAAS agonists and antagonists: clinical applications and controversies","volume":"11","author":"Romero","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0028","first-page":"777","article-title":"The renin-angiotensin-aldosterone system (RAAS): beyond cardiovascular regulation","volume":"12","author":"Valentini","year":"2025","journal-title":"Vet Sci"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.70163","article-title":"Renin inhibition and eNOS upregulation as novel mechanisms of antihypertensive food peptides","volume":"44","author":"Ashaolu","year":"2026","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-007-9062-x","article-title":"Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review","volume":"13","author":"Stragier","year":"2008","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0031","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1007\/s00018-004-4246-1","article-title":"The angiotensin IV\/AT4 receptor","volume":"61","author":"Chai","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0032","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","volume":"393","author":"Munkhaugen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0033","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/eurjpc\/zwae346","article-title":"Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort","volume":"32","author":"Johner","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0034","article-title":"\u03b2-blocker use and health status among patients with heart failure with preserved ejection fraction","volume":"8","author":"Jawad","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0035","doi-asserted-by":"crossref","first-page":"14771","DOI":"10.1074\/jbc.M113.542589","article-title":"A long-lasting \u03b21-adrenergic receptor stimulation of cAMP\/protein kinase A signal in cardiac myocytes","volume":"289","author":"Fu","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0036","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/CIRCRESAHA.119.316319","article-title":"GRK5 controls SAP97-dependent cardiotoxic \u03b21-adrenergic receptor-CaMKII signaling in heart failure","volume":"127","author":"Xu","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003840","article-title":"Calcium\/calmodulin-dependent protein kinase II activity persists during chronic \u03b2-adrenoceptor blockade in experimental and human heart failure","volume":"10","author":"Dewenter","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/1440-1681.70011","article-title":"Oroxin B resembles bisoprolol in attenuating beta1-adrenergic receptor autoantibody-induced atrial remodeling via the PTEN\/AKT\/mTOR signaling pathway","volume":"52","author":"Yang","year":"2025","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0039","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cardfail.2016.03.005","article-title":"Autoantibodies specifically against \u03b21 adrenergic receptors and adverse clinical outcome in patients with chronic systolic heart failure in the \u03b2-blocker era: the importance of immunoglobulin G3 subclass","volume":"22","author":"Nagatomo","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamacardio.2023.3003","article-title":"Repurposing the beta3-adrenergic receptor agonist mirabegron in patients with structural cardiac disease: the Beta3-LVH phase 2b randomized clinical trial","volume":"8","author":"Balligand","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0041","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ejhf.714","article-title":"The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial","volume":"19","author":"Bundgaard","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0042","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/FJC.0000000000001545","article-title":"First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure: impact on diastolic function","volume":"83","author":"Bahrami","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262411844","article-title":"Therapeutic potential of the \u03b23-adrenergic receptor and its ligands in cardiovascular diseases","volume":"26","author":"Kempinski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0044","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association of the European Society of Cardiology","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jchf.2018.02.007","article-title":"Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure","volume":"6","author":"Vaduganathan","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0046","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2025.01.011","article-title":"Baseline NT-proBNP nonresponse score and health status measures in assessing treatment responses in heart failure with reduced ejection fraction","volume":"283","author":"Chaikijurajai","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0048","doi-asserted-by":"crossref","first-page":"e09","DOI":"10.15420\/cfr.2022.23","article-title":"Pathophysiological rationale and clinical evidence for neurohormonal modulation in heart failure with preserved ejection fraction","volume":"9","author":"Castiglione","year":"2023","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2019.08.040","article-title":"Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction","volume":"296","author":"Vergaro","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0050","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0051","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0052","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"J Endocrinol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0053","doi-asserted-by":"crossref","first-page":"60A","DOI":"10.1016\/S0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"62","author":"Swedberg","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0054","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0056","article-title":"Use of spironolactone for the treatment of heart failure with preserved ejection fraction: efficacy and clinical implications in light of recent evidence","volume":"17","author":"Maharjan","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0057","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0058","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1725782","article-title":"Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0060","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases: clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0062","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/heartjnl-2022-321730","article-title":"Diagnosis and management of resistant hypertension","volume":"110","author":"Camafort","year":"2024","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0063","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0064","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ebm1307","article-title":"Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction","volume":"16","author":"Ambrosy","year":"2011","journal-title":"Evid Based Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0066","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/07853890.2023.2171110","article-title":"Cardiorenal benefits of finerenone: protecting kidney and heart","volume":"55","author":"Gonz\u00e1lez-Juanatey","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0067","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ejhf.1308","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","volume":"20","author":"Sanders","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008293","article-title":"Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction","volume":"14","author":"Minamisawa","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0069","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/biomedicines14010101","article-title":"Dual inhibition of the renin-angiotensin-aldosterone system and sodium-glucose cotransporter-2: mechanistic and clinical evidence for cardiorenal protection","volume":"14","author":"Aazar","year":"2026","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103352_bib0071","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology","volume":"360","author":"Wright","year":"2021","journal-title":"Kidney"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0072","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12882-019-1490-z","article-title":"Role of sodium\/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage","volume":"20","author":"Reyes Pardo","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0073","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/jcmm.14233","article-title":"Angiotensin II-induced redox-sensitive SGLT1 and SGLT2 expression promotes high glucose-induced endothelial cell senescence","volume":"24","author":"Khemais Benkhiat","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0074","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal antifibrotic effect of sodium-glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310710","article-title":"Cardioprotective effects of sodium-glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension are mediated by the local reduction of sympathetic activity and inflammation","volume":"24","author":"Castoldi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0076","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF-\u03b21\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103352_bib0077","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/ehf2.14313","article-title":"Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure","volume":"10","author":"Bosch","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0078","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative review of immunomodulatory and anti-inflammatory effects of sodium-glucose cotransporter 2 inhibitors: unveiling novel therapeutic frontiers","volume":"9","author":"Lee","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176712","article-title":"Dapagliflozin attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling","volume":"978","author":"Zhan","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0080","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1007\/s10753-025-02309-1","article-title":"Sodium-glucose cotransporter 2 inhibitor ameliorates angiotensin II-induced hypertension and vascular injury by upregulating FGF21","volume":"48","author":"Dai","year":"2025","journal-title":"Inflammation"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0081","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.3390\/ijms26188960","article-title":"One syndrome, many faces: a unified perspective on heart failure phenotypes","volume":"26","author":"Paraskevaidis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0082","article-title":"Comparison of pharmacological treatment effects on long-term outcomes in heart failure with preserved ejection fraction: a network meta-analysis of randomized controlled trials","volume":"12","author":"Lin","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0083","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41569-020-0363-2","article-title":"Evaluation and management of heart failure with preserved ejection fraction","volume":"17","author":"Borlaug","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0084","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31963","article-title":"Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis","volume":"5","author":"Xiang","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0086","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"von Haehling","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0087","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","article-title":"PARAGON-HF investigators. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction","volume":"74","author":"Shah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0088","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0089","article-title":"Emerging therapeutic strategies for heart failure: a comprehensive review of novel pharmacological and molecular targets","volume":"17","author":"Palaparthi","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000000929","article-title":"Cardiac myosin activation for the treatment of systolic heart failure","volume":"77","author":"Bernier","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0091","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0092","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0093","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hfc.2017.12.006","article-title":"Gene editing and gene-based therapeutics for cardiomyopathies","volume":"14","author":"Ohiri","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0094","doi-asserted-by":"crossref","first-page":"77","DOI":"10.34172\/jcvtr.2022.14","article-title":"A glance at the application of CRISPR\/Cas9 gene-editing technology in cardiovascular diseases","volume":"14","author":"Roshanravan","year":"2022","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0095","first-page":"1","article-title":"Application and potential of artificial intelligence in heart failure","volume":"54","author":"Yoon","year":"2024","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cpcardiol.2026.103352_bib0096","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/s12872-025-05173-x","article-title":"The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:30:02Z","timestamp":1778549402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0146280626000940"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103352","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quadruple therapy in heart failure: Why, when, and in whom?","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103352"}}